Compare AGEN & EPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGEN | EPM |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 165.9M |
| IPO Year | 1999 | 1996 |
| Metric | AGEN | EPM |
|---|---|---|
| Price | $3.47 | $4.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $14.50 | $4.83 |
| AVG Volume (30 Days) | ★ 889.8K | 389.3K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.08% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | $42,877,086.00 | ★ $43,229,621.00 |
| Revenue This Year | $107.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.48 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $2.71 | $3.19 |
| 52 Week High | $7.34 | $5.70 |
| Indicator | AGEN | EPM |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 50.62 |
| Support Level | $2.91 | $4.38 |
| Resistance Level | $4.72 | $4.63 |
| Average True Range (ATR) | 0.25 | 0.16 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 24.30 | 53.80 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.